company background image
PTGX

Protagonist Therapeutics NasdaqGM:PTGX Stock Report

Last Price

US$9.08

Market Cap

US$441.8m

7D

15.5%

1Y

-79.2%

Updated

24 Jun, 2022

Data

Company Financials +
PTGX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PTGX Stock Overview

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases.

Protagonist Therapeutics Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Protagonist Therapeutics
Historical stock prices
Current Share PriceUS$9.08
52 Week HighUS$50.54
52 Week LowUS$6.91
Beta2.59
1 Month Change15.52%
3 Month Change-63.62%
1 Year Change-79.18%
3 Year Change-25.02%
5 Year Change-19.72%
Change since IPO-22.39%

Recent News & Updates

Jun 15
We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Jun 08

Protagonist: Too Many Red Flags

Protagonist has recently faced a number of mishaps. These make the stock risky. They have a good deal of cash for now.

May 11
Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

Celebrations may be in order for Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) shareholders, with the analysts...

Shareholder Returns

PTGXUS BiotechsUS Market
7D15.5%10.3%6.6%
1Y-79.2%-24.4%-18.5%

Return vs Industry: PTGX underperformed the US Biotechs industry which returned -25.1% over the past year.

Return vs Market: PTGX underperformed the US Market which returned -20.5% over the past year.

Price Volatility

Is PTGX's price volatile compared to industry and market?
PTGX volatility
PTGX Average Weekly Movement18.5%
Biotechs Industry Average Movement13.0%
Market Average Movement8.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: PTGX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.

Volatility Over Time: PTGX's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2006122Dinesh Patelhttps://www.protagonist-inc.com

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics Fundamentals Summary

How do Protagonist Therapeutics's earnings and revenue compare to its market cap?
PTGX fundamental statistics
Market CapUS$441.80m
Earnings (TTM)-US$122.48m
Revenue (TTM)US$46.89m

9.4x

P/S Ratio

-3.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PTGX income statement (TTM)
RevenueUS$46.89m
Cost of RevenueUS$0
Gross ProfitUS$46.89m
Other ExpensesUS$169.37m
Earnings-US$122.48m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.52
Gross Margin100.00%
Net Profit Margin-261.21%
Debt/Equity Ratio0%

How did PTGX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is PTGX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PTGX?

Other financial metrics that can be useful for relative valuation.

PTGX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3x
Enterprise Value/EBITDA-1.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does PTGX's PS Ratio compare to its peers?

PTGX PS Ratio vs Peers
The above table shows the PS ratio for PTGX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average4.2x

Price-To-Sales vs Peers: PTGX is expensive based on its Price-To-Sales Ratio (9.4x) compared to the peer average (4.2x).


Price to Earnings Ratio vs Industry

How does PTGX's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Sales vs Industry: PTGX is good value based on its Price-To-Sales Ratio (9.4x) compared to the US Biotechs industry average (13.8x)


Price to Sales Ratio vs Fair Ratio

What is PTGX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PTGX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio9.4x
Fair PS Ratio94.3x

Price-To-Sales vs Fair Ratio: PTGX is good value based on its Price-To-Sales Ratio (9.4x) compared to the estimated Fair Price-To-Sales Ratio (94.3x).


Share Price vs Fair Value

What is the Fair Price of PTGX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PTGX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PTGX's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PTGX's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Protagonist Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


31.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PTGX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PTGX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PTGX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PTGX's revenue (64.5% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: PTGX's revenue (64.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PTGX is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Protagonist Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-25.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PTGX is currently unprofitable.

Growing Profit Margin: PTGX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PTGX is unprofitable, and losses have increased over the past 5 years at a rate of 25.2% per year.

Accelerating Growth: Unable to compare PTGX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PTGX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: PTGX has a negative Return on Equity (-40.59%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Protagonist Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PTGX's short term assets ($341.5M) exceed its short term liabilities ($43.5M).

Long Term Liabilities: PTGX's short term assets ($341.5M) exceed its long term liabilities ($3.1M).


Debt to Equity History and Analysis

Debt Level: PTGX is debt free.

Reducing Debt: PTGX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PTGX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PTGX has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 32.4% each year.


Discover healthy companies

Dividend

What is Protagonist Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PTGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PTGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PTGX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PTGX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PTGX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Dinesh Patel (64 yo)

13.5yrs

Tenure

US$5,544,733

Compensation

Dr. Dinesh V. Patel, Ph D., has been the Chief Executive Officer and President at Protagonist Therapeutics, Inc. since December 2008 and was its Interim Chief Financial Officer till May 28, 2019. Dr. Patel...


CEO Compensation Analysis

Compensation vs Market: Dinesh's total compensation ($USD5.54M) is above average for companies of similar size in the US market ($USD2.71M).

Compensation vs Earnings: Dinesh's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PTGX's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

Experienced Board: PTGX's board of directors are considered experienced (7.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.5%.


Top Shareholders

Company Information

Protagonist Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Protagonist Therapeutics, Inc.
  • Ticker: PTGX
  • Exchange: NasdaqGM
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$441.798m
  • Shares outstanding: 48.66m
  • Website: https://www.protagonist-inc.com

Number of Employees


Location

  • Protagonist Therapeutics, Inc.
  • 7707 Gateway Boulevard
  • Suite 140
  • Newark
  • California
  • 94560-1160
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/24 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.